Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT capsules versus placebo to prevent infection-related hospital presentation in cirrhosis
ISRCTN17863382Phase 3Recruiting
- Sponsor
- King's College Hospital
- Start
- Jun 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of allogeneic fecal microbiota in Cirrhosis, sponsored by King's College Hospital. Primary endpoints: Time to first infection resulting in emergency department presentation or hospital admission and Decompensating episodes resulting in emergency department presentation or hospital admission. Started Jun 2023; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ISRCTN17863382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17863382.